Targeted therapy in relapsed classical hodgkin lymphoma.
Although frontline treatment of advanced Hodgkin lymphoma (HL) produces high cure rates, disease either will not respond to or will relapse after initial therapy in approximately a quarter of patients. Many patients with disease relapse can be successfully salvaged with second-line chemotherapy followed by autologous stem cell transplantation (ASCT). Patients whose disease relapses after ASCT are rarely cured. A unique pathophysiologic feature of HL is that the malignant Reed-Sternberg (HRS) cell is rare and resides within a microenvironment of inflammatory and immune-related cells. The recent FDA approval of the anti-CD30 antibody-drug conjugate brentuximab vedotin (BV) for patients with either primary refractory HL or those whose disease relapses after ASCT represents a major advance in therapy. This article focuses on BV and other novel agents that target the HRS cell surface, intracellular signaling pathways, and tumor microenvironment.
From the Department of Medicine (Oncology), Stanford University School of Medicine, Stanford, California.
Shira
S
Dinner
Ranjana
R
Advani
D000079963:Brentuximab Vedotin; D018572:Disease-Free Survival; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000276:immunology*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D016539:Reed-Sternberg Cells / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous; D059016:Tumor Microenvironment / Q000187:drug effects
D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin